|
|
Upfront Briefing
Welcome back from the long weekend — Novartis didn't get one. Del-desiran, the asset carrying roughly a third of the projected peak sales behind its $12B Avidity buyout, missed in Phase 3 HARBOR this morning and took the stock down more than 10%. That is two failed readouts in four days, after pelacarsen lowered Lp(a) across 8,323 patients on Friday without moving a single outcome. Novo added to the cardiology misery, binning HERMES and ATHENA and leaving ziltivekimab one trial from retirement. The counterpunch came from FDA, which cleared AstraZeneca's camizestrant on a blood-test trigger five months after its own advisers voted 6-3 against it. ERS runs in Barcelona through Wednesday.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,718.6 |
(0.4%) |
+12.5% |
| Nasdaq 100 |
29,544.2 |
+0.2% |
+17.2% |
| Russell 2000 |
2,975.6 |
+0.2% |
+18.6% |
| Healthcare (XLV) |
171.4 |
(1.0%) |
+10.3% |
| Biotech (XBI) |
163.8 |
(0.3%) |
+34.4% |
| Nasdaq Biotech (NBI) |
7,236.3 |
(0.8%) |
+26.8% |
| Clinical Trials (BBC) |
53.7 |
+0.6% |
+42.7% |
|
- Healthcare was the weak sector on Friday, XLV (1.0%) against the S&P's (0.4%), while XBI (0.3%) held up better than cap-weighted healthcare; Novartis' pelacarsen miss and the camizestrant approval both crossed that day.
- The broad tape split rather than sold off — Nasdaq 100 +0.2% and Russell 2000 +0.2% against a lower S&P — with the 10-year at 4.784% and VIX up 5.3% to 15.30 into the long weekend; US markets were then closed Monday 7 September for Labor Day.
- Market data: U.S. cash close Friday, 4 September 2026.
The Big 3
|
1
|
Novartis loses del-desiran, the heart of its $12B Avidity buy
|
- Novartis said the Phase 3 HARBOR trial of del-desiran missed its primary endpoint of video hand opening time in myotonic dystrophy type 1, with clinical activity seen in secondary and exploratory analyses. Shares fell more than 10%; the company held its 5-6% sales CAGR guidance to 2030.
- Why it matters: Del-desiran was the centrepiece of the $12B Avidity buyout, and Jefferies puts it at roughly a third of that deal's projected peak sales. Michael Leuchten's note argues the damage goes beyond one trial. HARBOR ran 159 patients dosed every eight weeks against a novel endpoint, which leaves Novartis room to argue the measure failed rather than the molecule — a harder case to make now that this is the second Phase 3 miss in four days after pelacarsen, and the third setback in a week counting the rap-cel deaths. Del-zota holds FDA priority review in DMD44, but del-brax Phase 3 data does not land until 2028. A 16x 2027 multiple against a sub-13x sector needs wins to defend it.
- Source: STAT
- More: Endpoints; Fierce Biotech
|
|
2
|
Novo halts two more Phase 3 ziltivekimab trials
|
- Novo Nordisk told investigators on Friday it is ending the Phase 3 HERMES (n=4,900) and ATHENA (n=673) trials of ziltivekimab early on a data monitoring committee recommendation, leaving ARTEMIS as the IL-6 antibody's last remaining outcomes study.
- Why it matters: Two more stops leave ziltivekimab with one shot left. HERMES and ATHENA both tested the antibody in heart failure with mildly reduced or preserved ejection fraction, and the committee concluded neither would land differently from ZEUS, which missed on MACE at a hazard ratio of 0.99 in July. ARTEMIS, in post-heart-attack patients, still reads out in the first half of 2027 and now carries the entire thesis. Novo paid $725M upfront for Corvidia in 2020 to acquire the molecule and has already flagged a third-quarter impairment. IL-6 lowering keeps engaging its target and keeps missing hard endpoints, which is a problem for anyone still funding inflammation-led cardiovascular programmes.
- Source: STAT
- More: Fierce Biotech; Endpoints
|
| 3 | FDA clears camizestrant on a blood test, overruling its own panel |
- FDA granted accelerated approval to AstraZeneca's camizestrant (Etcamah) with a CDK4/6 inhibitor in HR-positive, HER2-negative advanced breast cancer once ctDNA detects an emergent ESR1 mutation, and cleared Guardant360 CDx as the companion diagnostic.
- Why it matters: This is the first FDA approval that turns a blood test into a treatment trigger. SERENA-6 randomised 315 patients already on an aromatase inhibitor plus a CDK4/6 inhibitor and switched them the moment ctDNA showed an ESR1 mutation, before any scan showed progression; median PFS was 16.0 months against 9.2, hazard ratio 0.44. ODAC voted 6-3 against in April on exactly that point, arguing molecular relapse is not clinical benefit. FDA took the supplemental ctDNA analyses and cleared it anyway. Guardant360 riding along as the CDx is the trade most people will miss here. Accelerated approval means the confirmatory obligation is still outstanding.
- Source: Endpoints
- More: ASCO Post; CancerNetwork
|
Everything Else that broke
- FDA approved Ionis' Zanvastro (zilganersen) for Alexander disease, the first disease-modifying treatment for the disorder and more than two weeks ahead of its 22 September PDUFA date; Ionis also collected a rare pediatric disease priority review voucher. — BioSpace
- ERS Congress opened in Barcelona on 5 September, with the first Phase 3 data for an IL-33 receptor antagonist in COPD exacerbation prevention and first-in-human results for a TSLP/IL-4Rα bispecific. — HCPLive
- Menarini took European rights to Gan & Lee's once-every-two-weeks GLP-1 bofanglutide, which has cleared Phase 3 in China and Phase 2 in the US. — Fierce Biotech
- TScan cut 75% of staff and narrowed its focus to solid tumors. — BioSpace
- A base-editing therapy reported durable remission in SCD and β-thalassemia, including 100% transfusion independence in Chinese TDT patients. — PR
- Moderna and Merck's mRNA manufacturing focus is shifting toward individualized vaccine delivery at scale. — BioSpace
- Insightec said EMEA focused ultrasound treatments topped 10,000 patients across more than 62 centers. — PR
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Menarini / Gan & Lee — European licence to GLP-1 bofanglutide: €62M ($72M) upfront, up to €664M ($771M) in milestones plus double-digit royalties, covering 39 countries including the EU-27, UK and Switzerland. — Fierce Biotech
VC / Private Financings
- Superluminal Medicines — $60M Series B, with BVF Partners, Deep Track Capital, Perceptive Advisors, RA Capital Management, Insight Partners and NVIDIA participating alongside Catalio Capital Management and Eli Lilly. — Fierce Biotech
- NeuShen — $80M, logged to Fierce's 2026 fundraising tracker on 7 September. — Fierce Biotech
IPOs / Follow-Ons
- ADARx — filed to go public, backed by AbbVie, to bankroll clinical trials of next-gen siRNA medicines. — Fierce Biotech
Academic Corner - Six proteomic aging clocks were applied in a Phase 2a trial to assess simultaneous geroprotective effects. — Nature Biotech
- One of the first randomized AI-in-medicine trials argues the next test is better patient outcomes, not clinician matching. — Nature Medicine
- A Nature Medicine piece reviewed TRACE lessons for strengthening clinical-trial ethics and regulatory oversight in Africa. — Nature Medicine
|
Three Novartis readouts, one survivor. Basel is having a week.
— BioBucks Team
|
|
|
